Theravance Biopharma (TBPH)
(Real Time Quote from BATS)
$8.62 USD
-0.08 (-0.92%)
Updated Jun 11, 2024 10:12 AM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
TBPH 8.62 -0.08(-0.92%)
Will TBPH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TBPH
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Other News for TBPH
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
Theravance Biopharma (TBPH) Receives a Hold from TD Cowen
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)
Tracking Seth Klarman's Baupost Group Holdings - Q1 2024 Update
Buy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline Prospects